JP2019510014A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510014A5
JP2019510014A5 JP2018546872A JP2018546872A JP2019510014A5 JP 2019510014 A5 JP2019510014 A5 JP 2019510014A5 JP 2018546872 A JP2018546872 A JP 2018546872A JP 2018546872 A JP2018546872 A JP 2018546872A JP 2019510014 A5 JP2019510014 A5 JP 2019510014A5
Authority
JP
Japan
Prior art keywords
peptide
dose
less
glp
section
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546872A
Other languages
English (en)
Japanese (ja)
Other versions
JP7237590B6 (ja
JP7237590B2 (ja
JP2019510014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/055679 external-priority patent/WO2017153575A1/en
Publication of JP2019510014A publication Critical patent/JP2019510014A/ja
Priority to JP2022177486A priority Critical patent/JP2023011864A/ja
Publication of JP2019510014A5 publication Critical patent/JP2019510014A5/ja
Application granted granted Critical
Publication of JP7237590B2 publication Critical patent/JP7237590B2/ja
Publication of JP7237590B6 publication Critical patent/JP7237590B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546872A 2016-03-10 2017-03-10 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト Active JP7237590B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022177486A JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306121P 2016-03-10 2016-03-10
US62/306,121 2016-03-10
PCT/EP2017/055679 WO2017153575A1 (en) 2016-03-10 2017-03-10 Glucagon and glp-1 co-agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022177486A Division JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Publications (4)

Publication Number Publication Date
JP2019510014A JP2019510014A (ja) 2019-04-11
JP2019510014A5 true JP2019510014A5 (https=) 2022-11-24
JP7237590B2 JP7237590B2 (ja) 2023-03-13
JP7237590B6 JP7237590B6 (ja) 2023-03-28

Family

ID=58266629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546872A Active JP7237590B6 (ja) 2016-03-10 2017-03-10 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト
JP2022177486A Pending JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022177486A Pending JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Country Status (19)

Country Link
US (3) US10676517B2 (https=)
EP (1) EP3426284B1 (https=)
JP (2) JP7237590B6 (https=)
KR (2) KR20220150416A (https=)
CN (1) CN108697769A (https=)
AR (1) AR107890A1 (https=)
AU (2) AU2017229530B2 (https=)
BR (1) BR112018067731A2 (https=)
CA (1) CA3015922A1 (https=)
EA (1) EA201891946A1 (https=)
ES (1) ES2983409T3 (https=)
IL (1) IL261528B2 (https=)
MX (1) MX2018010640A (https=)
MY (1) MY191321A (https=)
NZ (1) NZ746784A (https=)
SG (2) SG11201806342SA (https=)
TW (1) TWI793069B (https=)
WO (1) WO2017153575A1 (https=)
ZA (1) ZA201806637B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139613A1 (en) * 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EA202290107A1 (ru) 2019-07-01 2022-03-29 Медиммун Лимитед Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
KR102812908B1 (ko) 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
JP2023505126A (ja) * 2019-12-03 2023-02-08 メディミューン，エルエルシー 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CA3201539A1 (en) * 2020-12-07 2022-06-16 Vyjayanthi Krishnan Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20250067206A (ko) 2023-11-07 2025-05-15 주식회사 천농바이오푸드 대사성 질환의 예방, 개선 또는 치료 효과를 갖는 채소 추출복합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
AU2010272944B2 (en) * 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
DK2694095T3 (en) * 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists

Similar Documents

Publication Publication Date Title
JP7237590B6 (ja) 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト
JP2019510014A5 (https=)
US11230584B2 (en) Glucagon/GLP-1 agonists for the treatment of obesity
JP2016512213A (ja) 肥満の治療のためのペグ化グルカゴン及びｇｌｐ−１コアゴニスト
JP2013511287A (ja) ポリペプチド・コンジュゲート
EA043848B1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
NZ785999A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
US20210213104A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK1216179B (en) Glucagon/glp-1 agonists for the treatment of obesity